Title: Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy
Authors: Beel, Karolien
Janssens, Ann
Verhoef, Gregor
Vandenberghe, Peter # ×
Issue Date: Dec-2009
Publisher: Pergamon Press
Series Title: Leukemia Research vol:33 issue:12 pages:1703-1705
Abstract: In this letter we describe two case reports of CML patients with acquired mutations of the BCR-ABL1 kinase domain, in whom the mutant clone regressed and drug sensitivity was restored after temporary interruption of TKI. We believe that temporary interruption of an ATP-competitive tyrosine kinase inhibitor and switching to non-selective therapy can be a valid therapeutic option in CML patients. In addition, we highlight the potential of a flow cytometric CRKL phosphorylation assay to explore TKI sensitivity in CML cells ex vivo, and its correlation with clinical and haematological sensitivity or resistance.
ISSN: 0145-2126
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory for Genetics of Malignant Disorders
Department of Human Genetics - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
BeelE-pub.pdfpublisher's version pdf Published 299KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science